language Türkçe
LK

Li, Kan

2 papers · 385 citations · 2023–2024

Publications
2
Citations
385
Years
2
Publications
Title Year Type Citations
Health-related quality of life (HRQOL) with pembrolizumab (pembro) plus trastuzumab (tras) and chemotherapy (chemo) in first-line HER2-positive (HER2+) advanced gastric cancer: KEYNOTE-811 trial results
JOURNAL OF CLINICAL ONCOLOGY
2024 Meeting Abstract 1
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
LANCET
2023 Article 384